Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Ose Immunotherapeutics S.A.
Industry Sector: HealthTechnology
CEO: Nicolas Poirier, PhD
Number Of Employees: 55
Enterprise Value: $122,361,767
PE Ratio: 3.13
Exchange/Ticker 1: Euronext Paris:OSE
Exchange/Ticker 2: N/A
Latest Market Cap: $155,345,349
BioCentury | Jan 15, 2025
Management Tracks
Auspitz becomes managing partner at Curie.bio
Plus: Amphista names Paul Medeiro CBO, and updates from Apellis, Forbion, Eqt, Egle, Spero, Molecular Templates and more
BioCentury | Dec 3, 2024
Management Tracks
Bob Valamehr to succeed CEO Scott Wolchko at Fate
Plus: Amoolya Singh named CTO of Delfi and updates from Torl, OSE and George Clinical
BioCentury | May 29, 2024
Deals
Deals Report: Three $1B+ takeouts highlight demand in immunology, renal
Plus: Takeda-Degron to develop molecular glue degraders; Lilly-Aktis collaborate on radiopharmaceuticals; and more
BioCentury | Mar 5, 2024
Deals
Deals report: BridgeBio taps Bayer as EU partner
Plus: Viatris deal extends Idorsia’s runway; AbbVie-OSE; Merck KGaA-C4
BioCentury | Sep 8, 2023
Management Tracks
CRISPR CEO Kulkarni named chair as Novak departs
Plus: updates from Vividion, Rapport, One Biosciences, enGene, Anokion and more
BioCentury | Oct 12, 2022
Management Tracks
Wiggins, Simon join C-suite at Vaxcyte
Plus AZ’s Sheldon joining GSK (at last) and updates from Sudo, Walden, 1910 and more
BioCentury | Jul 14, 2022
Management Tracks
Cantrell joins Brii as CBO
Plus Chan Lee to be general counsel at BeiGene and updates from CytoDyn, Kezar, Anaveon, Fulcrum and more
BioCentury | Jan 19, 2022
Management Tracks
Interim no more: Zhang assumes Overland’s CEO post; Maraganore, Ho join as advisers
Plus: Merck KGaA strategy, R&D execs; and updates from CureVac, Exo, Krystal and more
BioCentury | Dec 22, 2021
Management Tracks
BIO’s McMurry-Heath joining Bioventus board
Plus: OSE, Centogene and OncoHealth
BioCentury | Feb 6, 2021
Product Development
Picking vaccine strategies that could hold up to COVID variants
COVID vaccines that induce broad polyclonal responses or potently enlist T cells could upstage single-antigen products when it comes to variants
Items per page:
1 - 10 of 28